Impact of 18F-FDG PET/CT in the management decisions of breast cancer board on early-stage breast cancer
- 17 October 2023
- journal article
- research article
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 26 (5) , 1139-1146
Abstract
Purpose Breast cancer is the most common malignancy accounting for 11.7% of all cancer cases, with a rising incidence rate. Various diagnostic methods, including 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18F-FDG PET/CT), play a crucial role in breast cancer diagnosis and staging. However, the unnecessary use of advanced imaging techniques such as PET/CT in early-stage breast cancer can have negative effects on both economics and patients. We aimed to investigate the impact of PET/CT on the management decisions of early-stage breast cancer patients by the breast cancer tumor board. Methods A retrospective analysis was performed on a cohort of 81 patients with early-stage breast cancer who were evaluated by breast cancer tumor board from January 2015 to December 2020. Demographic, clinical, and radiographic data, along with surgical procedures and treatment options, were documented and analyzed. Results The results showed that 18F-FDG PET/CT had a moderate impact on treatment decisions of breast cancer tumor board, as only treatment decisions were changed in 14,86% of the patients. The surgical procedure decision of breast cancer tumor board changed in 12.35% of patients, while 87.65% of patients had consistent decisions before and after PET/CT. Pathological assessments revealed invasive ductal carcinoma as the most prevalent tumor type, and molecular subtypes were predominantly luminal B. PET/CT use had limited impact on surgical procedures and did not significantly alter treatment decisions of breast cancer tumor board in this early-stage breast cancer cohort. Conclusions In conclusion, this study highlights the importance of adherence to the guidelines and appropriate use of PET/CT in early-stage breast cancer management. PET/CT should be reserved for cases where it is clinically warranted, considering the potential economic burden and minimal impact on treatment decisions of breast cancer tumor board in this patient population.Keywords
This publication has 29 references indexed in Scilit:
- Variation in the use of advanced imaging at the time of breast cancer diagnosis in a statewide registryCancer, 2017
- The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population‐based to a more “personalized” approach to cancer stagingCA: A Cancer Journal for Clinicians, 2017
- Incidence and Mortality and Epidemiology of Breast Cancer in the WorldAsian Pacific Journal of Cancer Prevention, 2016
- Is PET/CT Necessary in the Management of Early Breast Cancer?Clinical Nuclear Medicine, 2016
- Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015Annals of Oncology, 2015
- Breast Cancer in Turkey: Clinical and Histopathological Characteristics (Analysis of 13.240 Patients)Journal of Breast Health, 2014
- Advanced Imaging Modalities in Early Stage Breast Cancer: Preoperative Use in the United States Medicare PopulationAnnals of Surgical Oncology, 2012
- Clinical impact of 18F-FDG PET/CT on initial staging and therapy planning for breast cancerExperimental and Therapeutic Medicine, 2012
- The value of 18-FDG PET/CT in early-stage breast cancer compared to traditional diagnostic modalities with an emphasis on changes in disease stage designation and treatment planEuropean Journal of Surgical Oncology, 2012
- Breast Cancer in Developing Countries: Opportunities for Improved SurvivalJournal of Oncology, 2010